

Supplemental Digital Content 2: Distribution of First Line ART Regimen among Adult ART Enrollees in Mozambique during 2004-2013


SDC 2a: Distribution of First-Line ART Regimen among Male ART Enrollees



SDC 2b: Distribution of First-Line ART Regimen among Non-Pregnant Female ART Enrollees



SDC 2c: Distribution of First-Line ART Regimen for Pregnant Female ART Enrollees



Abbreviations: AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; D4T, stavudine; TDF, tenofovir; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.

SDC 2d: Table of First-Line Antiretroviral Therapy Regimens among Adult ART Enrollees during 2004-2013

	Original		Imputed									<u> </u>	
	n	%	-	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
AZT+3TC+NVP													
Overall	149,410	49%	49%	5%	3%	4%	8%	9%	13%	58%	80%	81%	58%
Male	45,297	47%	45%	5%	2%	2%	3%	4%	9%	54%	77%	77%	67%
Non-pregnant Female	87,494	51%	50%	4%	3%	3%	7%	8%	12%	59%	80%	82%	65%
Pregnant Female	16,619	54%	54%	60%	14%	40%	52%	51%	46%	75%	86%	88%	30%
AZT+3TC+EFV													
Overall	15,023	5%	5%	0.2%	0.2%	0.3%	0.3%	0.3%	1%	3%	5%	6%	13%
Male	5,246	5%	5%	0.1%	0.3%	0.2%	0.4%	0.4%	1%	4%	7%	10%	10%
Non-pregnant Female	6,263	4%	4%	0.3%	0.2%	0.3%	0.2%	0.3%	1%	2%	4%	4%	9%
Pregnant Female	3,514	11%	11%	0%	0%	1%	0%	0%	0%	1%	1%	1%	24%
D4T+3TC+NVP													
Overall	98,665	32%	34%	86%	88%	82%	78%	77%	73%	31%	10%	9%	5%
Male	35,404	36%	37%	85%	87%	82%	79%	78%	75%	33%	10%	8%	6%
Non-pregnant Female	59,531	35%	36%	86%	89%	84%	80%	79%	75%	31%	11%	9%	6%
Pregnant Female	3,730	12%	12%	40%	82%	45%	41%	43%	47%	20%	10%	9%	2%
D4T+3TC+EFV													
Overall	12,522	4%	4%	6%	6%	10%	9%	8%	7%	4%	2%	2%	2%
Male	6,127	6%	6%	6%	8%	12%	12%	12%	10%	5%	3%	4%	3%
Non-pregnant Female	6,125	4%	4%	6%	6%	8%	7%	6%	6%	3%	2%	2%	2%
Pregnant Female	270	1%	1%	0.0%	1%	4%	2%	2%	2%	1%	1%	0%	1%
TDF+3TC+NVP													
Overall	314	0.1%	0.1%	0.0%	0.0%	0.3%	0.2%	0.0%	0.2%	0.1%	0.0%	0.0%	0.2%
Male	93	0.1%	0.1%	0.0%	0.1%	0.4%	0.3%	0.0%	0.1%	0.1%	0.0%	0.0%	0.1%
Non-pregnant Female	151	0.1%	0.1%	0.0%	0.0%	0.2%	0.2%	0.0%	0.2%	0.1%	0.0%	0.0%	0.1%
Pregnant Female	70	0.2%	0.2%	0.0%	0.0%	1%	0%	0.0%	0%	0%	0%	0%	0%
TDF+3TC+EFV													
Overall	15,209	5%	5%	0.1%	0.0%	1%	3%	2%	2%	1%	0%	0%	20%
Male	2,769	3%	3%	0.0%	0.1%	1%	3%	1%	1%	1%	0.3%	0.1%	12%
Non-pregnant Female	6,692	4%	4%	0.0%	0.0%	2%	3%	2%	2%	1%	0.2%	0.1%	16%
Pregnant Female	5,748	19%	19%			2%	1%	1%	1%	0%	0%	0%	40%
PI-based regimens	,												
Overall	4,118	1%	1%	2%	1%	1%	1%	3%	3%	2%	1%	1%	1%
Male	1,283	1%	1%	2%	2%	1%	1%	3%	3%	2%	1%	1%	1%
Non-pregnant Female	2,464	1%	2%	2%	1%	1%	1%	4%	3%	2%	1%	1%	1%
Pregnant Female	371	1%	1%	0.0%	0.0%	2%	1%	3%	2%	1%	1%	0%	1%
Triple NRTI regimens													
Overall	1,199	0.4%	0%	0.1%	0.2%	0.3%	0.2%	0.1%	0.3%	1%	0.3%	1%	0%
Male	330	0.3%	0.3%	0.2%	0.3%	0.2%	0.2%	0.1%	0.2%	1%	0.3%	0.5%	0.3%
Non-pregnant Female	734	0.4%	0.4%	0.0%	0.1%	0.2%	0.2%	0.1%	0.3%	1%	0.4%	1%	0.3%
Pregnant Female	135	0.4%	0.4%		1%	5%	1%	0%	1%	1%	0%	0%	0%
Other	100	01170	0,0	•	1,0	2 70	1,0	0,70	170	1,0	0,70	0,70	0,70
Overall	2,334	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Male	769	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Non-pregnant Female	1,320	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Pregnant Female	245	1%	1%	0.0%	1%	1%	0%	1%	1%	2%	1%	1%	1%
Missing	7,541	2%	1 /0	0.070	1 /0	1 /0	0 /0	1 /0	1 /0	270	1 /0	1 /0	1 /0
Abbreviations: AZT, zidovudine:				c . D	47D . 1'	TIDE . C	· DI	1.1.11.	AIDEL 1	• • •			

Abbreviations: AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; D4T, stavudine; TDF, tenofovir, PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor